Complement Ther Med. 2014 Aug;22(4):601-6. doi: 10.1016/j.ctim.2014.05.004. Epub 2014 May 13.
Effect of Royal Jelly on premenstrual syndrome among Iranian medical sciences students: a randomized, triple-blind, placebo-controlled study.
Taavoni S1, Barkhordari F2, Goushegir A3, Haghani H4.
Author informationAbstract
BACKGROUND:
OBJECTIVES:
METHOD:
RESULTS:
CONCLUSIONS:
KEYWORDS:
Premenstrual syndrome (PMS) may have negative effects on women's health and sometimes need therapeutic non-pharmacological management.
To determine the effect of oral consumption of 1000 mg Royal Jelly capsule on premenstrual syndrome.
This is a randomized, triple-blind, placebo-controlled clinical trial, which was conducted in Tehran University of Medical Sciences female dormitories between December 2011 and October 2012. The study population comprised 110 medical sciences student with PMS,
whom were randomly assigned to an intervention or a control group. Each
participant in the intervention group took one Royal jelly capsule
orally per day, starting on the first day of menstruation and continued
the same treatment daily throughout two consecutive menstrual cycles,
while participants in the intervention group took placebo capsules as
same method. The outcome measure in this study was PMS score as obtained through the Premenstrual Profile 2005.
The
mean of personal characteristics and baseline level of the premenstrual
score before intervention did not differ between groups. After two
consecutive months consumption of Royal Jelly, PMS
score had decreased from 23.17 ± 17.43 to 11.42 ± 14.58 (mean change:
11.75; 95% confidence interval [CI]: 8.31-15.19) and in Placebo, PMS
score changed from 21.48 ± 16.39 to 20.27 ± 15.76 (mean change: 1.20;
95% CI: -1.69 to 4.10). Also difference between mean changes was
significant (mean difference: 10.54; 95% CI: 6.10-14.98).
The results of the study have demonstrated that 2 months consumption of Royal Jelly was effective in reducing PMS.
Copyright © 2014. Published by Elsevier Ltd.
Copyright © 2014. Published by Elsevier Ltd.